AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

DZ Bank significantly raises TP for AbbVie

Analyst upgrade AI-generated analysis

πŸ“ˆ AbbVie shares gained 2.27% to $301.54 after a strong quarterly performance that exceeded market expectations.

πŸ’° Q3 revenue reached $17.4 billion, marking a 10% year-over-year increase in line with analyst forecasts.

🧬 The Immunology division drove growth with sales rising 16% to $9.2 billion as Skyrizi and Rinvoq replace Humira.

πŸ“ˆ Management raised the full-year revenue forecast by $200 million to a new total of $67.8 billion.

πŸ’΅ Adjusted EPS guidance midpoint was increased by $0.11 to reach $13.97 per share.

πŸ† DZ Bank maintains a buy rating and raises its target price significantly from $288 to $345.

Bullish Signals
  • AbbVie shares rose 2.27% to $301.54 following a solid quarterly report that beat market expectations.
  • Q3 revenue reached $17.4 billion, up 10%, demonstrating strong top-line growth in line with analyst forecasts.
  • The Immunology division sales surged 16% to $9.2 billion as the company successfully transitions from Humira to Skyrizi and Rinvoq.
  • Management raised the full-year revenue forecast by $200 million to $67.8 billion, signaling confidence in future performance.
  • Adjusted EPS guidance midpoint was increased by $0.11 to $13.97, reflecting improved profitability outlook.
  • DZ Bank upgraded its target price from $288 to $345 while maintaining a buy rating on the stock.
Full Analysis
AbbVie (ABBV) shares rose 2.27% to $301.54 following a solid quarterly report that beat market expectations and included raised guidance. DZ Bank, a German financial institution, has maintained its buy rating on the pharmaceutical giant while significantly increasing its target price from $288 to $345. The bank highlighted that AbbVie's Q3 revenue reached $17.4 billion, representing a 10% increase and aligning with analyst expectations. Specifically, the Immunology division, which is central to the company's strategy, saw sales surge by 16% to $9.2 billion, driven by the successful transition from Humira to its successors, Skyrizi and Rinvoq. Management has further strengthened the outlook by raising the full-year revenue forecast by $200 million to $67.8 billion and increasing the midpoint of adjusted EPS guidance by $0.11 to $13.97. DZ Bank emphasizes that the continued expansion of Skyrizi and Rinvoq through new indications, alongside growth in other therapeutic areas like Epkinly and Juvmo, broadens the revenue base beyond Immunology.